Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroblastoma 9 Prostatic Neoplasms 3 Precancerous Conditions 3 Glioma 3 Astrocytoma 3 Adenomatous Polyposis Coli 3 Skin Neoplasms 2 Sarcoma, Ewing 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive 2 Medulloblastoma 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma, Basal Cell 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Typical Teratoid Rhabdoid Tumor 1 Stomach Neoplasms 1 Rhabdoid Tumor 1 Osteosarcoma Recurrent 1 Oligodendroglioma 1 Non-melanoma Skin Cancer 1 Neoplasms 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Keratosis, Actinic 1 Gastritis, Atrophic 1 Esophageal Neoplasms 1

Interventions

pembrolizumab 185 Gemcitabine 170 Paclitaxel 152 Carboplatin 137 Bevacizumab 128 Surveys and Questionnaires 118 Cisplatin 115 Docetaxel 114 Blood Specimen Collection 110 Cyclophosphamide 109 Exercise 108 Nivolumab 98 Fluorouracil 90 Capecitabine 86 Dexamethasone 81 Radiotherapy 80 Irinotecan 74 Standard of Care 69 Pemetrexed 68 Oxaliplatin 68 Leucovorin 64 Drug Therapy 64 Cetuximab 60 Erlotinib Hydrochloride 56 Sorafenib 53 atezolizumab 52 Ipilimumab 51 Doxorubicin 50 trametinib 47 Interviews as Topic 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Eflornithine × Clear all

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡